Several other analysts have also issued reports on TEVA. Piper Sandler lowered shares of Teva Pharmaceutical Industries from a neutral rating to an underweight rating and dropped their price target for the stock from $11.00 to $7.00 in a research report on Wednesday, May 4th. Sanford C. Bernstein upgraded shares of Teva Pharmaceutical Industries from a market perform rating to an outperform rating and set a $11.00 target price for the company in a research note on Friday, March 25th. UBS Group assumed coverage on Teva Pharmaceutical Industries in a report on Monday, June 13th. They set a neutral rating and a $10.00 price target for the company. Bank of America upgraded Teva Pharmaceutical Industries from an underperform rating to a neutral rating and set a $9.00 price objective on the stock in a research note on Tuesday, May 17th. Finally, Barclays upgraded Teva Pharmaceutical Industries from an equal weight rating to an overweight rating and lifted their target price for the stock from $11.00 to $13.00 in a research note on Tuesday, April 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of Hold and an average target price of $10.71.
Shares of Teva Pharmaceutical Industries stock opened at $7.71 on Friday. The firm has a market cap of $8.51 billion, a price-to-earnings ratio of -14.02, a price-to-earnings-growth ratio of 1.02 and a beta of 1.17. The stock’s 50-day moving average is $8.80 and its 200-day moving average is $8.54. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.07 and a quick ratio of 0.73. Teva Pharmaceutical Industries has a one year low of $7.23 and a one year high of $10.50.
In related news, VP Hafrun Fridriksdottir sold 130,000 shares of the company’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $8.22, for a total value of $1,068,600.00. Following the transaction, the vice president now directly owns 1,387 shares in the company, valued at $11,401.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.82% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Weiss Multi Strategy Advisers LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $393,000. Quantbot Technologies LP acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth about $110,000. Royal Bank of Canada grew its stake in Teva Pharmaceutical Industries by 21.6% during the first quarter. Royal Bank of Canada now owns 944,421 shares of the company’s stock worth $8,868,000 after buying an additional 167,556 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Teva Pharmaceutical Industries by 18.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 71,982 shares of the company’s stock valued at $675,000 after buying an additional 11,044 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Teva Pharmaceutical Industries by 1.2% in the 1st quarter. California State Teachers Retirement System now owns 1,225,575 shares of the company’s stock valued at $11,508,000 after buying an additional 14,277 shares in the last quarter. Institutional investors own 45.79% of the company’s stock.
About Teva Pharmaceutical Industries (Get Rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.